富血小板血浆治疗大转子疼痛综合征的双盲随机对照试验(HIPPO试验)方案
HIPPO试验为单中心、双盲、随机安慰剂对照研究,计划纳入102例经影像学确诊的臀中肌或臀小肌腱病伴肌腱止点肿胀(伴或不伴滑囊炎)的大转子疼痛综合征(GTPS)患者,随机接受超声引导下富血小板血浆(PRP)或生理盐水安慰剂注射。主要结局为国际髋关节结局工具-12(iHOT-12),随访至12个月,旨在评估PRP改善症状和功能的效果及持续时间。
要点
- PRP为自体血制品,含较高浓度生长因子,可能促进愈合和抗炎。
- 皮质类固醇是GTPS二线治疗,但长期效果有限,PRP可能为替代选择。
- 试验采用超声引导注射,主要结局为iHOT-12,随访12个月。
核心结论
- HIPPO试验旨在检验PRP治疗保守治疗失败的GTPS有效的假设,并评估其效果持续时间。
研究设计与样本
- 单中心、双盲、随机安慰剂对照研究,计划随机化102例GTPS患者至PRP组或安慰剂(生理盐水注射)组。
- 纳入标准为影像学确诊的臀中肌或臀小肌腱病伴肌腱止点肿胀,伴或不伴滑囊炎。
- 参与者接受一次超声引导下PRP或安慰剂注射至大转子滑囊及周围臀中肌/臀小肌腱。
- 主要结局为国际髋关节结局工具-12(iHOT-12),次要结局包括疼痛视觉模拟评分、EQ-5D-3L和改良Harris髋关节评分,在基线、3、6、12个月测量。
- 第6个月参与者可选择重复盲法注射或交叉至PRP组;主要和次要结局按意向性治疗原则分析。
关键数值与推荐
- 主要结局为iHOT-12;次要结局包括疼痛VAS、EQ-5D-3L和改良Harris髋关节评分。
- 结局测量时间点为基线、3、6和12个月。
- 第6个月可选择重复盲法注射或交叉至PRP组。
临床怎么用
- 若PRP被证实有效,可为保守治疗失败的GTPS患者提供一种替代皮质类固醇的注射治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Greater trochanteric pain syndrome (GTPS) is a painful condition characterised by pain around the greater trochanter usually affecting middle-aged women. The majority of patients will improve with conservative management such as physiotherapy and non-steroidal anti-inflammatory drugs (NSAIDs); however, if this fails then more invasive treatments including corticosteroid injections and surgery may be required. Platelet-rich plasma (PRP) is an autologous blood product, which has a higher concentration of growth factors postulated to provide enhanced healing and anti-inflammatory properties. There have been numerous studies on PRP's efficacy in musculoskeletal soft tissue conditions with similar pathology to GTPS, with varying results, most promising being in plantar fasciopathy and patellar tendinopathy. Corticosteroids are the established second-line treatment, but do not always work long term. PRP may be a suitable alternative to corticosteroid in GTPS with longer-term effects; however, there are very limited reports. The Hip Injections PRP Vs Placebo (HIPPO) trial aims to assess the ability of PRP to improve symptoms and function in patients with GTPS. METHODS/DESIGN: HIPPO is a single-centre, double-blind randomized placebo-controlled study in patients with a radiologically confirmed diagnosis of gluteus medius or minimus tendinopathy with swelling within the tendon insertion with or without bursitis. We aim to randomise 102 patients with GTPS to either the PRP or placebo (normal saline injection) treatment arm. Participants will receive one ultrasound (US) guided PRP/placebo injection into the trochanteric bursa and surrounding gluteus medius/minimus tendons. The primary outcome measure is the International Hip Outcome Tool-12. Secondary outcome measures will include a visual analogue score for pain, the three-level version of the EuroQol five-dimensional questionnaire and the modified Harris Hip Score. Outcomes will be measured at baseline, 3, 6 and 12 months. Participants will have the option at 6 months to have a repeat blinded injection or cross over to PRP. Analyses of primary and secondary outcomes will be made according to the intention-to-treat principle. The trial reporting will comply with Consolidated Standards of Reporting Trials (CONSORT) guidelines. DISCUSSION: The HIPPO study has been designed to test the hypothesis that PRP is effective in treating GTPS in patients who have failed conservative management and to assess the duration of effect of PRP. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03479190 . Registered on 27 March 2018.
引用
- Oderuth E, Ali M, Atchia I, et al. A double blind randomised control trial investigating the efficacy of platelet rich plasma versus placebo for the treatment of greater trochanteric pain syndrome (the HIPPO trial): a protocol for a randomised clinical trial. Trials. 2018. PMID: 30241561. doi:10.1186/s13063-018-2907-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。